MR2938 relieves DSS-induced colitis in mice through inhibiting NF-κB signaling and improving epithelial barrier

Abstract

Damage to the epithelial barrier is among key processes contributing to initiation and chronic inflammation in inflammatory bowel diseases (IBD). Only management therapy exists for IBD (e.g., anti-inflammatory and immunomodulatory agents, JAK/STAT inhibitors), and while novel therapeutic approaches have shown great potential, issues remain including route of administration, development of resistance to therapy and toxicity. Thus, novel small molecule inhibitors which can alleviate colonic inflammation and restore intestinal barrier functions are needed. Our previous study identified a new quinazolinone derivative MR2938, inspired by marine natural product penipanoid C, displaying impressive anti-inflammatory effects. In vivo efficacy study indicated that MR2938 had a dose-dependent effect on improving colitis symptoms, gut-barrier disruption, and colonic inflammation in an acute dextran sulfate sodium (DSS)-induced murine colitis as a model of epithelial injury relevant to IBD. Evaluation of potential mechanism involved in MR2938 efficacy demonstrated that MR2938 inhibited NF-κB-mediated inflammatory responses, and attenuated intestinal epithelial tight junction damage by restoring the expression of Occludin and ZO-1. Taken together, these data suggest that MR2938 is a promising lead compound for the treatment of IBD.

Keywords

Inflammatory bowel diseases / Inflammation / NF-κB signaling / Barrier function

References

[1] Akther M, Haque ME, Park J, Kang T-B, Lee K-H. Nlrp3 ubiquitination-a new approach to target nlrp3 inflammasome activation. Int J Mol Sci. 2021, 22: 8780

[2] Al-Sadi RM, Ma TY. Il-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol. 2007, 178: 4641-4649

[3] Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, et al. . The cost of inflammatory bowel disease in high-income settings: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2023, 8: 458-492

[4] Chen J, Xu L, Zhang X-Q, Liu X, Zhang Z-X, Zhu Q-M, Liu J-Y, Iqbal MO, Ding N, Shao C-L, Wei M-Y, Gu Y-C. Discovery of a natural small-molecule amp-activated kinase activator that alleviates nonalcoholic steatohepatitis. Mar Life Sci Technol. 2023, 5: 196-210

[5] Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010, 2 a002907

[6] Grootjans J, Hundscheid IHR, Lenaerts K, Boonen B, Renes IB, Verheyen FK, Dejong CH, von Meyenfeldt MF, Beets GL, Buurman WA. Ischaemia-induced mucus barrier loss and bacterial penetration are rapidly counteracted by increased goblet cell secretory activity in human and rat colon. Gut. 2013, 62: 250-258

[7] Gustafsson JK, Johansson MEV. The role of goblet cells and mucus in intestinal homeostasis. Nat Rev Gastroenterol Hepatol. 2022, 19: 785-803

[8] Haas AJ, Zihni C, Ruppel A, Hartmann C, Ebnet K, Tada M, Balda MS, Matter K. Interplay between extracellular matrix stiffness and jam-a regulates mechanical load on zo-1 and tight junction assembly. Cell Rep. 2020, 32 107924

[9] Hu J, Wang Y, Li Y, Cao D, Xu L, Song S, Damaneh MS, Li J, Chen Y, Wang X, Chen L, Shen J, Miao Z, Xiong B. Structure-based optimization of a series of selective bet inhibitors containing aniline or indoline groups. Eur J Med Chem. 2018, 150: 156-175

[10] Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active crohn’s disease. Gastroenterology. 2004, 126: 989-996

[11] Kiely CJ, Pavli P, O’Brien CL. The microbiome of translocated bacterial populations in patients with and without inflammatory bowel disease. Intern Med J. 2018, 48: 1346-1354

[12] Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. Nat Rev Dis Primers England. 2020, 6: 74

[13] Kotla NG, Isa ILM, Rasala S, Demir S, Singh R, Baby BV, Swamy SK, Dockery P, Jala VR, Rochev Y, Pandit A. Modulation of gut barrier functions in ulcerative colitis by hyaluronic acid system. Adv Sci (Weinh). 2022, 9 e2103189

[14] Kudelka MR, Stowell SR, Cummings RD, Neish AS. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in ibd. Nat Rev Gastroenterol Hepatol. 2020, 17: 597-617

[15] Kuo W-T, Zuo L, Odenwald MA, Madha S, Singh G, Gurniak CB, Abraham C, Turner JR. The tight junction protein zo-1 is dispensable for barrier function but critical for effective mucosal repair. Gastroenterology. 2021, 161: 1924-1939

[16] Kuo W-T, Odenwald MA, Turner JR, Zuo L. Tight junction proteins occludin and zo-1 as regulators of epithelial proliferation and survival. Ann N Y Acad Sci. 2022, 1514: 21-33

[17] Laurindo LF, de Santos AROD, de Carvalho ACA, Bechara MD, Guiguer EL, de Goulart RA, Vargas Sinatora R, Araújo AC, Barbalho SM. Phytochemicals and regulation of nf-kb in inflammatory bowel diseases: an overview of in vitro and in vivo effects. Metabolites. 2023, 13: 96

[18] Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther. 2020, 20: 363-378

[19] Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023, 402: 571-584

[20] Li R, Zhou Y, Zhang X, Yang L, Liu J, Wightman SM, Lv L, Liu Z, Wang C-Y, Zhao C. Identification of marine natural product pretrichodermamide b as a stat3 inhibitor for efficient anticancer therapy. Mar Life Sci Technol. 2023, 5: 94-101

[21] Liu Y, Yang M, Tang L, Wang F, Huang S, Liu S, Lei Y, Wang S, Xie Z, Wang W, Zhao X, Tang B, Yang S. Tlr4 regulates rorγt+ regulatory t-cell responses and susceptibility to colon inflammation through interaction with akkermansia muciniphila. Microbiome. 2022, 10: 98

[22] Liyanage NM, Nagahawatta DP, Jayawardena TU, Jeon Y-J. The role of seaweed polysaccharides in gastrointestinal health: protective effect against inflammatory bowel disease. Life (Basel). 2023, 13: 1026

[23] Lu Y, Chen H, Chen Y, Zhao L, Hou S. Accumulated lps induced by colitis altered the activities of vitamin d-metabolizing hydroxylases and decreased the generation of 25-hydroxyvitamin d. Chem Biol Interact. 2024, 395: 110997

[24] Lv L, Maimaitiming M, Huang Y, Yang J, Chen S, Sun Y, Zhang X, Li X, Xue C, Wang P, Wang CY, Liu Z. Discovery of quinazolin-4(3h)-one derivatives as novel ache inhibitors with anti-inflammatory activities. Eur J Med Chem. 2023, 254 115346

[25] Park J, Jeong GH, Song M, Yon DK, Lee SW, Koyanagi A, Jacob L, Kostev K, Dragioti E, Radua J, Cheon JH, Shin JI, Smith L. The global, regional, and national burden of inflammatory bowel diseases, 1990–2019: a systematic analysis for the global burden of disease study 2019. Dig Liver Dis. 2023, 55: 1352-1359

[26] Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Schölmerich J, Gross V. Nuclear factor kappab is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998, 115: 357-369

[27] Song Y, Yuan M, Xu Y, Xu H. Tackling inflammatory bowel diseases: targeting proinflammatory cytokines and lymphocyte homing. Pharmaceuticals (Basel). 2022, 15: 1080

[28] Teruel AH, Gonzalez-Alvarez I, Bermejo M, Merino V, Marcos MD, Sancenon F, Gonzalez-Alvarez M, Martinez-Mañez R. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy. Int J Mol Sci. 2020, 21: 6502-6531

[29] Twardowska A, Makaro A, Binienda A, Fichna J, Salaga M. Preventing bacterial translocation in patients with leaky gut syndrome: nutrition and pharmacological treatment options. Int J Mol Sci. 2022, 23: 3204

[30] Vallabhapurapu S, Karin M. Regulation and function of nf-kappab transcription factors in the immune system. Annu Rev Immunol. 2009, 27: 693-733

[31] Zahid A, Li B, Kombe AJK, Jin T, Tao J. Pharmacological inhibitors of the nlrp3 inflammasome. Front Immunol. 2019, 10: 2538

[32] Zhang W, Michalowski CB, Beloqui A. Oral delivery of biologics in inflammatory bowel disease treatment. Front Bioeng Biotechnol. 2021, 9 675194

RIGHTS & PERMISSIONS

The Author(s)